Pharma BD Deal Intelligence
A rare consumer-health M&A success: Mucinex is still Reckitt's #1 US OTC brand and a global powerbrand 17+ years later, with continued product launches and new US manufacturing investment as recently as 2024.
Full analysis, sources & comparables →Reckitt offered $60/share cash (~$2.3B) for Adams; CEO Bart Becht called Mucinex 'a market and innovation leader in cough and congestion relief in the USA' and…
Adams stock climbed sharply on the buyout news; analysts viewed the $60/share price as a clean exit reflecting Mucinex's brand strength but noted Reckitt is…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$60/share, ~$2.3B. Mucinex OTC respiratory franchise. Source: BioSpace, Drug Store News.
A rare consumer-health M&A success: Mucinex is still Reckitt's #1 US OTC brand and a global powerbrand 17+ years later, with continued product launches and new US manufacturing investment as recently as 2024.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. (this deal) | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |